Suprefact (buserelin acetate) / Sanofi 
Welcome,         Profile    Billing    Logout  
 11 Diseases   8 Trials   8 Trials   280 News 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Suprefact (buserelin acetate) / Sanofi
2006-001909-28: Ensayo clínico fase IV-III multicéntrico, prospectivo, aleatorizado, abierto y paralelo de 36 meses para evaluar la eficacia del bloqueo androgénico intermitente versus continuo en el tratamiento de la recidiva bioquímica del cáncer de próstata tratado con radioterapia.

Ongoing
4
180
Europe
BUSERELINA, GOSERELINA, LEUPRORELINA, TRIPTORELINA, SUPREFACT DEPOT, ZOLADEX TRIMESTRAL 10,8 mg, PROCRIN TRIMESTRAL, ELIGARD TRIMESTRAL, DECAPEPTYL TRIMESTRAL, SUPREFACT DEPOT, ZOLADEX TRIMESTRAL 10,8 mg, PROCRIN TRIMESTRAL, ELIGARD TRIMESTRAL 22,5 mg, DECAPEPTYL TRIMESTRAL, SUPREFACT DEPOT, ZOLADEX TRIMESTRAL 10,8 mg, PROCRIN TRIMESTRAL, ELIGARD TRIMESTRAL 22,5 mg, DECAPEPTYL TRIMESTRAL
Grupo GICOR
Cáncer de próstata tratado con radioterapia y que presenta recidiva bioquímica.
 
 
2011-004836-76: Can Suprefact be given every forth month instead of third month with the same effect on castration levels.

Ongoing
4
200
Europe
Suprefact, Suprefact (Buserelin), Suprefact (Buserelin)
Urologkliniken USÖ
Prostate cancer that need hormone treatment by LHRH-agoniste.
 
 
2012-004824-39: Comparison of two different drug protocols for ovarian stimulation in women with low egg reserve undergoing first attempt of in vitro fertilization

Not yet recruiting
4
60
Europe
cetrotide®, Suprecur®, Powder for solution for injection, Solution for injection, Cetrotide, buserelin
UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST, Merck Serono
response to ovarian stimulation in women with reduced ovarian reserve undergoing first cycle of in vitro fertilisaion., response to in vitro fertilisation treatment in women with predicted reduced number of eggs., Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
 
 
RTOG 0534, NCT00567580: Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Active, not recruiting
3
1792
Canada, US, RoW
PBRT, Prostate bed radiotherapy, Three-Dimensional Conformal Radiation Therapy (3D-CRT), Intensity modulated RT (IMRT), PLNRT, Pelvic lymph node radiotherapy, AA, flutamide, bicalutamide, LHRH agonist, leuprolide, goserelin, buserelin, triptorelin
Radiation Therapy Oncology Group, National Cancer Institute (NCI), Cancer and Leukemia Group B, NRG Oncology
Prostate Cancer
07/18
 
NCT00936390 / 2010-020825-42: Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Active, not recruiting
3
1538
Canada, US
bicalutamide, flutamide, anti-androgen therapy, LHRH agonist (antagonist) therapy, leuprolide, goserelin, buserelin, triptorelin, degarelix, Dose-Escalated Radiation Therapy
Radiation Therapy Oncology Group, National Cancer Institute (NCI), NRG Oncology
Prostate Cancer
10/20
10/25
NCT01546987: Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Active, not recruiting
3
239
Canada, US
GnRH agonist, LHRH analog, leuprolide, goserelin, buserelin, triptorelin, Gonadotropin-releasing hormone (GnRH) Agonist, LHRH agonist, Anti-androgen, flutamide, bicalutamide, androgen suppression, TAK-700, Radiation therapy
Radiation Therapy Oncology Group, National Cancer Institute (NCI), NRG Oncology
Prostate Cancer
11/21
06/29
NCT01492972: Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

Recruiting
3
192
US
Radiation, Androgen Suppression Therapy, leuprolide, goserelin, buserelin, or triptorelin
Proton Collaborative Group
Prostate Cancer
12/25
 
GUIDANCE, NCT05050084: Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score

Recruiting
3
2050
Canada, US
Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, ICI 123215, S74-6766, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, Degarelix, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, TAK 385, TAK-385, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma
04/32
04/37
PREDICT-RT, NCT04513717: Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The Trial

Recruiting
3
2478
Canada, US
Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, ICI 123215, S74-6766, Degarelix, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
12/33
12/33

Download Options